You may already know a lot of the names that are considered leaders of the diabetes technology industry. The likes of Abbott and Dexcom are leaders in the continuous glucose monitor (CGM) space. MiniMed, Insulet and Tandem Diabetes Care are a few of the companies with a significant share in the automated insulin delivery (AID) […]
Implants
Glucotrack combines with Lōkahi Therapeutics to become CBGM subsidiary
Glucotrack (Nasdaq:GCTK) announced that it completed a strategic business combination with Lōkahi Therapeutics. The companies structured the combination so that Lōkahi becomes the operating and controlling business of the combined company. It now leverages Glucotrack’s continuous blood glucose monitoring (CBGM) business as a wholly owned subsidiary. According to a news release, the combined organization integrates […]
Glucotrack expands IP to cover novel glucose monitor sensor architectures
Glucotrack (Nasdaq:GCTK) announced today that it secured new intellectual property allowance protecting its continuous blood glucose monitor (CBGM). The patent application, titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient,” was allowed by the U.S. Patent and Trademark Office (USPTO), expanding the IP protecting the CBGM as Glucotrack looks to advance […]
Vivani, Novo Nordisk partner to evaluate long-term semaglutide implant
Vivani Medical (Nasdaq:VANI) today announced a new agreement with Novo Nordisk to evaluate the NPM-139 long-term semaglutide implant. NPM-139 utilizes the Alameda, California-based company’s NanoPortal platform technology, under development for chronic weight management. Vivani designed NanoPortal technology to steadily deliver medication over extended periods of time. The company aims to guarantee correct doses for patients while […]
Senseonics, Welldoc partner on next-gen Eversense 365 app development
Senseonics (NYSE:SENS) and Welldoc today announced a strategic partnership to develop a new custom mobile application for Eversense 365. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. The implant […]
Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
Senseonics (NYSE:SENS) today announced real-world evidence supporting the performance of its Eversense 365 year-long CGM implant. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. Germantown, Maryland-based Senseonics said data […]
Glucotrack CEO explains tech behind long-term CBGM implant
Glucotrack (Nasdaq:GCTK) has made great strides over the past several years as it advances its implantable continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that […]
Elixir Medical study backs DynamX bioadaptor against drug-eluting stent
Elixir Medical today announced four-year results from a study comparing its DynamX coronary bioadaptor system to a leading drug-eluting stent (DES). The BIOADAPTOR randomized controlled trial compared DynamX to the Medtronic Resolute Onyx DES, the current standard of care. It compared the therapies across Japan, Europe and New Zealand. Investigators shared findings from 445 patients […]
Senseonics posts mixed Q1, raises 2026 guidance amid growing Eversense 365 sales
Senseonics (NYSE:SENS) today reported first-quarter financial results that exceeded Wall Street’s revenue expectations. However, shares of SENS ticked up 1.4% to $5.43 apiece in post-market trading today as the company reported recent advances with its diabetes technology and increased its guidance. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $32.3 […]
Glucotrack submits long-term implantable CBGM for FDA IDE
Glucotrack (Nasdaq:GCTK) announced today that it submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE. FDA IDE (investigational device exemption) would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack’s device features no on-body external component. The company aims to offer it for three years of […]
